Flag of the European Union EU Clinical Trials Register Help

Clinical trials for prostate cancer OR breast cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    815 result(s) found for: prostate cancer OR breast cancer. Displaying page 7 of 41.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2010-021886-63 Sponsor Protocol Number: RD2010-48 Start Date*: 2011-07-14
    Sponsor Name:East and North Hertfordshire NHS Trust [...]
    1. East and North Hertfordshire NHS Trust
    2.
    Full Title: A trial of Prostate Radiotherapy in Conjunction with Carbogen and Nicotinamide (PROCON)
    Medical condition: Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001120-29 Sponsor Protocol Number: GEN702 Start Date*: 2016-09-30
    Sponsor Name:Genmab A/S
    Full Title: Dose-escalating and cohort expansion safety trial of tissue factor specific antibody drug conjugate tisotumab vedotin (HuMax®-TF-ADC) in patients with locally advanced and/or metastatic solid tumor...
    Medical condition: Cancer of the ovary, cervix, endometrium, bladder, prostate (castration-resistant prostate cancer [CRPC]), esophagus or lung (non-small cell lung cancer [NSCLC])
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014742 Endometrial neoplasms malignant HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008342 Cervix carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023774 Large cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DK (Completed) BE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2008-005276-27 Sponsor Protocol Number: FE 200486 CS35 Start Date*: 2009-07-17
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: An Open-Label, Multi-Centre, Randomised, Parallel-Arm One-Year Trial, Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen with Goserelin Acetate in Patients with Prostate Canc...
    Medical condition: prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: HU (Completed) NL (Completed) DE (Completed) FI (Completed) CZ (Completed) GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-006674-22 Sponsor Protocol Number: 56021927PCR2046 Start Date*: 2022-12-12
    Sponsor Name:VÝCHODOSLOVENSKÝ ONKOLOGICKÝ ÚSTAV, a.s.
    Full Title: AD ASTRA (Androgen Deprivation with Apalutamide and STereotactic RAdiotherapy) Prospective institutional phase II study of efficacy and safety of androgen deprivation with apalutamide in high-risk ...
    Medical condition: Localized or a locally advanced high-risk prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-004257-24 Sponsor Protocol Number: PROSPETMR2021 Start Date*: 2022-09-05
    Sponsor Name:Uniwersytet Medyczny w Białymstoku
    Full Title: Multicentre Evaluation of Clinical Applications of Innovative PET/MRI with a 68Ga-PSMA-11 Radiotracer when Planning a Personalised Therapy in Prostate Cancer Patients
    Medical condition: Intermediate and high-risk prostate cancer before introduction of radical treatment and in patients diagnosed with biochemical failure following radical treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004458-14 Sponsor Protocol Number: PROvING Start Date*: 2020-11-05
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: Phase III clinical trial Oligometastatic and Oligorecurrent PROstate Cancer: enhancing patients’ selection by new ImagiNG biomarkers
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007453 Carcinoma of the prostate metastatic LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007454 Carcinoma of the prostate recurrent LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003585-34 Sponsor Protocol Number: METRO Start Date*: 2006-08-28
    Sponsor Name:
    Full Title: WEEKLY DOCETAXEL COMBINED WITH DAILY ORAL LOW DOSES OF PREDNISONE AND CYCLOPHOSPHAMIDE IN HORMONE-REFRACTORY PROSTATE CARCINOMA A PHASE I/II STUDY
    Medical condition: hormone refractory prostate carcinoma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10036908 HLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001266-29 Sponsor Protocol Number: PC-ARN-IPC-2015-025 Start Date*: 2017-02-09
    Sponsor Name:Institut Paoli Calmettes
    Full Title: Active surveillance with or without a 6 months Apalutamide treatment in low risk prostate cancer: a phase II randomized multicenter trial
    Medical condition: Low risk localized prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007113 Cancer of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004120-39 Sponsor Protocol Number: 1.0 Start Date*: 2017-03-13
    Sponsor Name:Region Skåne
    Full Title: An experimental pilot study on immune and inflammatory biomarkers in patients with advanced prostatecancer treated with degarelix vs. GnRH agonist and with cardiovascular disease
    Medical condition: Patients with advanced prostate cancer and pre-existing cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10036916 Prostate cancer stage D LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003027-21 Sponsor Protocol Number: RM2-01-01-14 Start Date*: 2015-03-30
    Sponsor Name:Piramal Imaging SA
    Full Title: Open-label, multi center PET/CT (positron emission tomography/computed tomography) study for investigation of safety and diagnostic performance of the 68Ga labeled PET tracer [68Ga]RM2 following a ...
    Medical condition: Patients with primary prostate cancer in which prostate cancer is histologically confirmed and a prostatectomy is planned.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Prematurely Ended) FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-004478-29 Sponsor Protocol Number: ASL606LIOM02 Start Date*: 2006-12-17
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST
    Full Title: DOCETAXEL AND PREDNISON IN ASSOCIATION WITH METRONOMIC THERAPY WITH CICLOPHOSPHAMIDE AND CELECOXIN IN HORMONE-REFRACTORY PROSTATIC CANCER PATIENTS : PHASE II CLINICAL TRIAL WITH PHARMACODYNAMIC AND...
    Medical condition: PATIENTS WITH PROSTATIC HORMONE-REFRACTORY CANCER
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001602-10 Sponsor Protocol Number: DCProst Start Date*: 2011-07-21
    Sponsor Name:Center for Cancer Immunotherapy (CCIT) / Department of Oncology, Herlev Hospital
    Full Title: Dendritic cell vaccination in combination with Docetaxel for patients with prostata cancer - a randomized phase II trial
    Medical condition: Castration resistent metastatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10036908 Prostatic neoplasms malignant HLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-004274-28 Sponsor Protocol Number: ASK-2-2011 Start Date*: 2011-09-21
    Sponsor Name:Erling Bjerregaard Pedersen, Medicinsk forskningsafsnit, Regionshospitalet Holstebro
    Full Title: Effect of hydroxyethyl starch on renal handling of sodium and water, vasoactive hormones,biomarkers and the circulatory system in patients undergoing radical prostatectomy
    Medical condition: Patients undergoing radical prostatectomy in generel anesthesia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007113 Cancer of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006154-17 Sponsor Protocol Number: 20080537 Start Date*: 2009-07-20
    Sponsor Name:Amgen Inc
    Full Title: An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastati...
    Medical condition: medical condition should be "Bone Loss in patients undergoing androgen-deprivation therapy (ADT) for non-metastatic prostate cancer"
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065687 Bone loss LLT
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed) CZ (Completed) HU (Completed) PL (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2009-014446-28 Sponsor Protocol Number: JANUS Start Date*: 2009-12-03
    Sponsor Name:UNIVERSITA` CAMPUS BIOMEDICO
    Full Title: A PHASE II TRANSLATIONAL STUDY INVESTIGATING THE BIOLOGICAL EFFECTS OF THE ZOLEDRONIC ACID AS NEOADJUVANT THERAPY ON INVASIVE PROSTATE CANCER
    Medical condition: invasive prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10036917 Prostate cancer stage I LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004371-51 Sponsor Protocol Number: PSMA-study Start Date*: 2017-01-30
    Sponsor Name:AZIENDA USL DELLA VALLE D'AOSTA
    Full Title: 68Ga-PSMA-PET/CT for detection of recurrent prostate cancer
    Medical condition: Biochemical recurrence in patients with prostate cancer after radical prostatectomy and/or radiotherapy, no CRPC status
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    20.1 100000004848 10036223 Positron emission tomography LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-003642-26 Sponsor Protocol Number: 3116001 Start Date*: 2014-12-17
    Sponsor Name:Orion Corporation Orion Pharma
    Full Title: SAFETY AND PHARMACOKINETICS OF ODM-204 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC): OPEN, NONRANDOMISED, UNCONTROLLED, MULTICENTRE, DOSE ESCALATION, FIRST-IN-MAN STUDY W...
    Medical condition: Metastatic castration resistant prostate cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036916 Prostate cancer stage D LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Completed) GB (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2009-013174-41 Sponsor Protocol Number: CRPC2 Start Date*: 2009-10-14
    Sponsor Name:Medivation, Inc.
    Full Title: AFFIRM: A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Patients with Progressive Castration-Resistant Prostate Cancer Previously ...
    Medical condition: Patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) GB (Completed) FR (Completed) ES (Completed) DE (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005193-11 Sponsor Protocol Number: METAL Start Date*: 2015-03-31
    Sponsor Name:King's College London [...]
    1. King's College London
    2. Guy's and St Thomas' NHS Foundation Trust
    Full Title: METformin And Longevity (METAL): A window of opportunity study investigating biological effects of metformin in localised prostate cancer
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-008604-40 Sponsor Protocol Number: FE200486 CS31 Start Date*: 2009-04-09
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: A randomised, parallel-arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of volume reduction of the prostate in patients with pro...
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) FI (Completed) DK (Completed) BE (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Apr 05 13:57:35 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA